Takeda files for Actos combination in Japan
This article was originally published in Scrip
Executive Summary
Takeda has filed for the approval in Japan of a fixed dose combination of Actos (pioglitazone) and glimepiride, a sulfonylurea, for the treatment of type 2 diabetes.